AXT Inc vs Tilray Brands Inc — how do they compare? AXT Inc trades at $78.86 (market cap $4.83B), while Tilray Brands Inc trades at $4.81 (market cap $649.42M). The key difference: AXT Inc is far larger — about 7.4× Tilray Brands Inc's market cap, and AXT Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | TLRY | |
|---|---|---|
Market Cap | $4.83B | $649.42M |
Sector | Technology | Health |
52-Week High | $140.83 | $21.00 |
52-Week Low | $2.05 | $3.88 |
Enterprise Value | $4.50B | $816.55M |
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $88.58, up 17.84% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat. The stock is technically bullish with support at $82 and resistance at $92. Fundamentally, revenue grew to $126 million in 2026 with a net profit margin of 3.23%, though valuation ratios like P/E of 2,460.33 appear elevated. Recent news highlights surging indium phosphide demand driven by AI data centers.
Outlook is positive with analyst consensus at Buy (72.73%) and a $72.50 price target, but risks include high valuation, cash flow volatility, and dependence on AI-driven demand. The stock offers growth exposure to semiconductor substrates, yet investors should weigh profitability sustainability against rich multiples.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →